On dihydroorotate dehydrogenases and their inhibitors and uses. - Institut Pasteur Access content directly
Journal Articles Journal of Medicinal Chemistry Year : 2013

On dihydroorotate dehydrogenases and their inhibitors and uses.

Hélène Munier-Lehmann
Frédéric Tangy
Yves Louis Janin
Connectez-vous pour contacter l'auteur


Proper nucleosides availability is crucial for the proliferation of living entities (eukaryotic cells, parasites, bacteria, and virus). Accordingly, the uses of inhibitors of the de novo nucleosides biosynthetic pathways have been investigated in the past. In the following we have focused on dihydroorotate dehydrogenase (DHODH), the fourth enzyme in the de novo pyrimidine nucleosides biosynthetic pathway. We first described the different types of enzyme in terms of sequence, structure, and biochemistry, including the reported bioassays. In a second part, the series of inhibitors of this enzyme along with a description of their potential or actual uses were reviewed. These inhibitors are indeed used in medicine to treat autoimmune diseases such as rheumatoid arthritis or multiple sclerosis (leflunomide and teriflunomide) and have been investigated in treatments of cancer, virus, and parasite infections (i.e., malaria) as well as in crop science.
No file

Dates and versions

pasteur-00819070 , version 1 (30-04-2013)



Hélène Munier-Lehmann, Pierre-Olivier Vidalain, Frédéric Tangy, Yves Louis Janin. On dihydroorotate dehydrogenases and their inhibitors and uses.. Journal of Medicinal Chemistry, 2013, 56 (8), pp.3148-67. ⟨10.1021/jm301848w⟩. ⟨pasteur-00819070⟩
60 View
0 Download



Gmail Facebook X LinkedIn More